Th1 responses to beta-amyloid in young humans convert to regulatory IL-10 responses in Down syndrome and Alzheimer's disease

Neurobiology of Aging

Volumn 31, Issue 10, 2010, Pages 1732-1742

  Loewenbrueck, Kai F ^a,b,c   Tigno Aranjuez, Justine T ^a   Boehm, Bernhard O ^b   Lehmann, Paul V ^a   Tary Lehmann, Magdalena ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Abeta; Adjuvant; Alzheimer; Autoimmune; Humans; Memory cells; T cells; Tolerance; Vaccination

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN SYNDROME; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; TH1 CELL;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CD4-POSITIVE T-LYMPHOCYTES; DOWN SYNDROME; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; MALE; MIDDLE AGED; MONOCYTES; PEPTIDE FRAGMENTS; TH1 CELLS; YOUNG ADULT;

EID: 77955842718     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.09.007     Document Type: Article

References (49)

1. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2:675-680. (Review) (84 refs.).
2. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
3. Berard M., Tough D.F. Qualitative differences between naive and memory T cells. Immunology 2002, 106:127-138.
4. Binder C.J., Hartvigsen K., Chang M.K., Miller M., Broide D., Palinski W., Curtiss L.K., Corr M., Witztum J.L. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 2004, 114:427-437.
5. Blasko I., Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging 2003, 20:101-113. (Review) (86 refs.).
6. Brettschneider S., Morgenthaler N.G., Teipel S.J., Fischer-Schulz C., Burger K., Dodel R., Du Y., Moller H.J., Bergmann A., Hampel H. Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. Biol. Psychiatry 2005, 57:813-816.
7. Campbell A. Beta-amyloid: friend or foe. Med. Hypotheses 2001, 56:388-391.
8. Ciaramella, A., Sanarico, N., Bizzoni, F., Moro, M.L., Salani, F., Scapigliati, G., Spalletta, G., Caltagirone, C., Bossu, P., 2007. Amyloid beta peptide promotes differentiation of pro-inflammatory human myeloid dendritic cells. Neurobiol. Aging, Epub ahead of print, PMID: 17658667 (PubMed - as supplied by publisher).
9. Das P., Murphy M.P., Younkin L.H., Younkin S.G., Golde T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 2001, 22:721-727.
10. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295:2264-2267.
11. Deng Y., Jing Y., Campbell A.E., Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J. Immunol. 2004, 172:3437-3446.
12. Du Y., Dodel R., Hampel H., Buerger K., Lin S., Eastwood B., Bales K., Gao F., Moeller H.J., Oertel W., Farlow M., Paul S. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001, 57:801-805.
13. Ferrer I., Boada R.M., Sanchez Guerra M.L., Rey M.J., Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14:11-20.
14. Finch C.E., Marchalonis J.J. Evolutionary perspectives on amyloid and inflammatory features of Alzheimer disease. Neurobiol. Aging 1996, 17:809-815. (Review) (131 refs.).
15. Guerkov R.E., Targoni O.S., Kreher C.R., Boehm B.O., Herrera M.T., Tary-Lehmann M., Lehmann P.V., Schwander S.K. Detection of low-frequency antigen-specific IL-10-producing CD4(+) T cells via ELISPOT in PBMC: cognate vs. nonspecific production of the cytokine. J. Immunol. Methods 2003, 279:111-121.
16. Haynes L., Swain S.L. Why aging T cells fail: implications for vaccination. Immunity 2006, 24:663-666.
17. Helms T., Boehm B.O., Asaad R.J., Trezza R.P., Lehmann P.V., Tary-Lehmann M. Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J. Immunol. 2000, 164:3723-3732.
18. Horwitz D.A., Zheng S.G., Gray J.D. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J. Leukocyte Biol. 2003, 74:471-478. (Review) (87 refs.).
19. Isacson O., Seo H., Lin L., Albeck D., Granholm A.C. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci. 2002, 25:79-84. (Review) (77 refs.).
20. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995.
21. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982. (see comment).
22. Karulin A.Y., Hesse M.D., Tary-Lehmann M., Lehmann P.V. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity. J. Immunol. 2000, 164:1862-1872.
23. Mason D. T-cell-mediated control of autoimmunity. Arthritis Res. 2001, 3:133-135.
24. Meierhoff G., Ott P.A., Lehmann P.V., Schloot N.C. Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes. Diab./Metab. Res. Rev. 2002, 18:367-380. (Review) (80 refs.).
25. Miscia S., Ciccocioppo F., Lanuti P., Velluto L., Bascelli A., Pierdomenico L., Genovesi D., Di Siena A., Santavenere E., Gambi F., Ausili-Cefaro G., Grimley P.M., Marchisio M., Gambi D. Abeta(1-42) stimulated T cells express P-PKC-delta and P-PKC-zeta in Alzheimer disease. Neurobiol. Aging 2007.
26. Monsonego A., Zota V., Karni A., Krieger J.I., Bar-Or A., Bitan G., Budson A.E., Sperling R., Selkoe D.J., Weiner H.L. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 2003, 112:415-422. (see comment).
27. Moore K.W., de Waal M.R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Ann. Rev. Immunol. 2001, 19:683-765. (Review) (661 refs.).
28. Muzio M., Bosisio D., Polentarutti N., D'amico G., Stoppacciaro A., Mancinelli R., van't Veer C., Penton-Rol G., Ruco L.P., Allavena P., Mantovani A. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 2000, 164:5998-6004.
29. O'Garra A., Vieira P. Regulatory T cells and mechanisms of immune system control. Nat. Med. 2004, 10:801-805. (Review) (65 refs.).
30. Ott P.A., Herzog B.A., Quast S., Hofstetter H.H., Boehm B.O., Tary-Lehmann M., Durinovic-Bello I., Berner B.R., Lehmann P.V. Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls. Clin. Immunol. 2005, 115:102-114.
31. Ott P.A., Tary-Lehmann M., Lehmann P.V. The secretory IFN-gamma response of single CD4 memory cells after activation on different antigen presenting cell types. Clin. Immunol. 2007, 124:267-276.
32. Palinski W., Horkko S., Miller E., Steinbrecher U.P., Powell H.C., Curtiss L.K., Witztum J.L. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 1996, 98:800-814.
33. Pawelec G., Hirokawa K., Fulop T. Altered T cell signalling in ageing. Mech. Ageing Dev. 2001, 122:1613-1637. (Review) (143 refs.).
34. Pelfrey C.M., Rudick R.A., Cotleur A.C., Lee J.C., Tary-Lehmann M., Lehmann P.V. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J. Immunol. 2000, 165:1641-1651.
35. Pifer J., Hennes J.L., Lee J.M., Witte P.L. Age-related differences in the immune response to immunization with human Abeta42 peptide. J. Gerontol. Ser. A-Biol. Sci. Med. Sci. 2002, 57:B355-B358.
36. Rentzos M., Paraskevas G.P., Kapaki E., Nikolaou C., Zoga M., Rombos A., Tsoutsou A., Vassilopoulos D.D. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J. Neurol. Sci. 2006, 249:110-114.
37. Rosenkranz D., Weyer S., Tolosa E., Gaenslen A., Berg D., Leyhe T., Gasser T., Stoltze L. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J. Neuroimmunol. 2007, 188:117-127.
38. Russo D.M., Kozlova N., Lakey D.L., Kernodle D. Naive human T cells develop into Th1 effectors after stimulation with Mycobacterium tuberculosis-infected macrophages or recombinant Ag85 proteins. Infect. Immun. 2000, 68:6826-6832.
39. Sakata-Kaneko S., Wakatsuki Y., Matsunaga Y., Usui T., Kita T. Altered Th1/Th2 commitment in human CD4+ T cells with ageing. Clin. Exp. Immunol. 2000, 120:267-273.
40. Sandmand M., Bruunsgaard H., Kemp K., Andersen-Ranberg K., Pedersen A.N., Skinhoj P., Pedersen B.K. Is ageing associated with a shift in the balance between Type 1 and Type 2 cytokines in humans?. Clin. Exp. Immunol. 2002, 127:107-114.
41. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177. (see comment).
42. Schindowski K., Frohlich L., Maurer K., Muller W.E., Eckert A. Age-related impairment of human T lymphocytes' activation: specific differences between CD4(+) and CD8(+) subsets. Mech. Ageing Dev. 2002, 123:375-390.
43. Shearer G.M., Clerici M. Cytokine profiles in HIV type 1 disease and protection. AIDS Res. Human Retroviruses 1998, 14(Suppl 2):S149-S152. (Review) (41 refs.).
44. Trieb K., Ransmayr G., Sgonc R., Lassmann H., Grubeck-Loebenstein B. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol. Aging 1996, 17:541-547.
45. Udan M.L., Ajit D., Crouse N.R., Nichols M.R. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J. Neurochem. 2008, 104:524-533.
46. Weksler M.E., Goodhardt M. Do age-associated changes in 'physiologic' autoantibodies contribute to infection, atherosclerosis, and Alzheimer's disease?. Exp. Gerontol. 2002, 37:971-979. (Review) (48 refs.).
47. Weksler M.E., Relkin N., Turkenich R., LaRusse S., Zhou L., Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 2002, 37:943-948.
48. Yang Z., Chen M., Wu R., Fialkow L.B., Bromberg J.S., McDuffie M., Naji A., Nadler J.L. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J. Immunol. 2002, 168:6479-6485.
49. Yip H.C., Karulin A.Y., Tary-Lehmann M., Hesse M.D., Radeke H., Heeger P.S., Trezza R.P., Heinzel F.P., Forsthuber T., Lehmann P.V. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 1999, 162:3942-3949.